OKYO Stock Forecast & Price Target

OKYO Pharma Ltd is showing robust progress in its biopharmaceutical development, particularly with its lead drug, Urcosimod, which has demonstrated favorable safety and tolerability in Phase 2 trials for dry eye disease (DED). The reported statistically significant improvements in symptoms such as stinging, burning, and ocular pain, which intersect with neuropathic corneal pain, highlight Urcosimod's potential for broader therapeutic applications. The positive results from these trials suggest a strong foundation for future drug approval and market adoption, contributing to an optimistic outlook for the company's stock.

OKYO Pharma Ltd faces significant risks that contribute to a negative outlook on its stock, primarily related to the clinical development of its lead therapeutic candidate, OK-101. The potential failure of OK-101 in clinical trials and the subsequent inability to secure regulatory approval in the U.S., coupled with challenges in achieving commercial success against competition and market size limitations, further exacerbate these concerns. Additionally, the risk of dilution poses a threat to shareholder value, highlighting the precarious nature of the company’s financial stability moving forward.